Released Nov 7, 2011, after the close
10-Q filed Nov 7, 2011, 38 days after period end · 0001144204-11-061636
Q3 2011 · 10-Q
Revenue$1.13M$1.13M −64.4% vs Q3 2010+48.2% vs Q2 2011
Net Income-$8.88M-$8.88M N/M vs Q3 2010N/M vs Q2 2011
EPS Diluted-$0.10-$0.10 N/M vs Q3 2010N/M vs Q2 2011
Gross Profit$677,000−68.1%
Operating Income-$8,767,000N/M
Operating Cash Flowderived-$8,147,000N/M
Free Cash Flowderived-$9,132,000N/M
Margins · derived
Gross margin59.8%−6.7 pt vs Q3 2010
Operating margin-774.5%−685.0 pt vs Q3 2010
Net margin-784.0%−706.3 pt vs Q3 2010
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2011 | Q3 2010 |
|---|---|---|
| Revenue | $1.13M | $3.18M |
| Net Income | -$8.88M | -$2.47M |
| EPS Diluted | -$0.10 | $0.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR